Devicare has obtained the patent in Europe and the United States for its electrochemical ion sensor, which is integral to the Lit-Control® pH Meter product for frequent urinary conditions, thus making progress in its intellectual and industrial protection strategy and gaining access to key markets in medical and health technologies.

The approval of this product profile by the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO) can be rather difficult, so “this is a very important milestone that brings our company to the fore, focused as we are on developing innovative products to treat and monitor chronic patients in the field of Digital Therapeutics, as well as highlighting the investment that we are implementing both in R&D and in intellectual and industrial property”, explains Lidia Casas, IP Manager at Devicare.

At the present time, Devicare has a significant portfolio of 49 patents granted and pending in the main countries of commercial interest, corresponding to nine different inventions that protect the company’s products.

Sensor to measure urinary pH

Thanks to this advanced sensor technology it has been possible to develop Lit-Control® pH Meter, the only device certified for medical use that precisely measures and controls urinary pH levels. Regular management of urinary pH (acidity of the urine) and monitoring it allows for the prevention and maintenance of good urinary system health. This constitutes a new medical approach endorsed by the medical community for responding to the increase in very painful frequently occurring urinary conditions such as renal lithiasis, overactive bladder, urinary infections, painful bladder syndrome, etc. and improving these patients’ quality of life.

Devicare envisages extending this patent to more countries in the coming months.

Logo_EPO_100px Logo_USPTO_100px